US006011066A

United States Patent [19]

Wang

[11] **Patent Number: 6,011,066**

[45] **Date of Patent: Jan. 4, 2000**

[54] **METHOD FOR TREATING SEPTIC SHOCK**

[75] Inventor: **Soo-Ray Wang**, Talpei, Taiwan

[73] Assignee: **Veterans General Hospital-Taipei**, Taipei, Taiwan

[21] Appl. No.: **09/017,433**

[22] Filed: **Feb. 2, 1998**

[51] **Int. Cl.**[7] **A61K 31/52**; A61K 31/195

[52] **U.S. Cl.** **514/561**; 518/563; 518/564; 518/566; 518/567; 518/616; 518/626; 518/629; 518/649; 518/653; 518/654; 518/663; 518/673; 514/674

[58] **Field of Search** 514/561, 563, 514/564, 566, 567, 616, 626, 629, 649, 653, 654, 663, 673, 674

[56] **References Cited**

U.S. PATENT DOCUMENTS

4,388,318	6/1983	Koyama et al.	424/251
4,822,776	4/1989	Cerami et al.	514/21
5,028,627	7/1991	Kilbourn et al.	514/565
5,068,314	11/1991	Nakamura et al.	530/317
5,162,571	11/1992	Shiraishi et al.	514/237.5
5,171,739	12/1992	Scott	514/12
5,175,183	12/1992	Brooks et al.	514/438
5,286,739	2/1994	Kilbourn et al.	514/400
5,306,710	4/1994	Wei	514/12
5,334,380	8/1994	Kilbourn et al.	424/85.2
5,374,651	12/1994	Kibourn et al.	514/400
5,436,270	7/1995	Wang	514/565
5,502,055	3/1996	Wang	514/250
5,530,113	6/1996	Christ et al.	536/123.13
5,534,545	7/1996	Kilbourn et al.	514/565
5,576,350	11/1996	Wang	514/565
5,594,113	1/1997	Wainwright et al.	530/395
5,656,608	8/1997	Schneider et al.	514/42

FOREIGN PATENT DOCUMENTS

WO9411370 5/1994 WIPO .

OTHER PUBLICATIONS

Souba, W.W., et al., "The role of glutamine in maintaining a healthy gut and supporting the metabolic response to injury and infection", J. Surg. Res. 1990 Apr.; 48(4):383–391.

Ardawi, M.S., "Effect of glutamine–enriched total parenteral nutrition on septic rats", Clin. Sci. (Colch) 81 (2): 215–222 (Aug. 1991).

Clowes, et al. "Effects of parenteral alimentation on amino acid metabolism in septic patients", Surgery, vol. 88, No. 4, pp. 531–543, Oct. 1980.

Primary Examiner—Frederick Krass
Attorney, Agent, or Firm—Christie, Parker & Hale, LLP

[57] **ABSTRACT**

A method for the treating septic shock in a patient comprises administering to the patient a therapeutically-effective amount of a composition comprising a compound having the formula (I):



(I)

wherein R_1 is hydrogen, hydroxyl, carboxyl, amino or C_1–C_8alkyl; R_2 is hydrogen, hydroxyl, amino or C_1–C_8 alkyl; and R_3 is hydrogen, hydroxyl, carboxyl, amino, C_1–C_8 alkyl, substituted or unsubstituted phenyl, amide, C_3–C_8 aminoalkyl, or C_1–C_8 aminoalkylcarbonyl; or a therapeutically-effective salt, ester or solvate thereof. Particularly preferred compounds for use in the present invention include butylamine, propylamine, diaminopropane, diaminobutanone, tyrosine, threonine, asparagine, and aspartate.

29 Claims, No Drawings